Delivery Order SPE2DB22D1103-SPE2DB25FTNW2
- Not listed
- The Defense Logistics Agency awarded a $4,843.93 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 8, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. The contract represents a single delivery order...
- The Defense Logistics Agency awarded a $13,075.97 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens, 40 mg/0.4 mL dosage. This contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This non-competitive, firm fixed-price delivery order is valued at $116,800.12 and is due for completion by August 5, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,529.47 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL pharmaceutical supply. This contract, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a $9,257.14 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of HUMIRA (adalimumab) prefilled pens, 40 mg/0.4 mL. This non-competitive, competitively awarded contract is structured as a firm fixed price delivery order with a completion date of July 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its pharmaceutical distribution...
- The Defense Logistics Agency awarded a delivery order valued at $9,063.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of August 5, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. The contract is valued at $12,513.37 under a firm fixed-price arrangement with no set-aside designation, reflecting a competitively awarded procurement. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of May 5, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,054.51 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL pharmaceutical supply. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $17,995.93 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL pharmaceutical supplies. This non-set-aside, competitively awarded contract was issued on June 17, 2025, with an ultimate completion date of June 18, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $3,828.03 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The supplies will be...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FTNW2Delivery Order
The Defense Logistics Agency awarded a $1,510.60 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL on June 3, 2025, with performance in Conshohocken, Pennsylvania. This is a firm fixed price, non-set-aside contract with a completion date of June 4, 2025. The delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a significant presence in federal medical procurement through its extensive contract portfolio with the Defense Logistics Agency. The company supplies a broad range of pharmaceutical products and medical supplies to support Defense Health Agency operations and other federal healthcare systems. This HUMIRA delivery order exemplifies the company's capability to fulfill critical biopharmaceutical needs through competitively awarded contracts under the DLA's pharmaceutical prime vendor framework, which is structured to provide flexible and reliable access to medications across multiple therapeutic domains for military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 6/3/25 |